Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Brain Cancer treatment details. Chemotherapy. Radiation. Duke University Medical Center, Durham, NC, United States

Survival: 20.5 months
Toxicity Grade: 4
Treatments: Chemotherapy
Country: United States
City/State/Province: Durham, NC
Hospital: Duke University Medical Center
Journal: Link
Date: 8/2009

Patients: This study involved 85 newly diagnosed patients with glioblastoma multiforme. Forty-nine of the patients had a median age of 54, ranging from 24 to 76 years. The other thirty-six patients had a median age of 56, ranging from 32 to 69 years. There were 55 men and 30 women.

Treatment: Patients were treated with radiation and chemotherapy with temozolomide. About half (36) were also treated with carmustine wafers. These patients also were treated with other (rotational multi-agent) chemotherapy drugs, but these were not described in detail.

Toxicity: Grade 3 or 4 seizures, thrombocytopenia, leukopenia, and seizures were more common in the group treated with carmustine. Of these, thrombocytopenia was the most common, reported in 17% of patients treated with carmustine. Fatigue and gastrointestinal toxicities (grade 2 to 4) were more common in patients not treated with carmustine.

Results: The median overall survival was 20.58 months (89.5 weeks) for patients treated with the multi-modality therapy that included carmustine, and 16.7 months (72.7) for those treated with only radiation, temozolomide, and the other chemotherapy drugs.

Correspondence: Dr. Henri S. Friedman

E-mail to a Friend Email Physician More Information